Related Experiment Videos
P53 gene mutations in pleuropulmonary blastomas.
Takeshi Kusafuka1, Seika Kuroda, Masahiro Inoue
1Department of Pediatric Surgery, Osaka University Medical School, Suita, Japan. kusafuka@pedsurg.med.osaka-u.ac.jp
Pediatric Hematology and Oncology
|March 8, 2002
Summary
p53 gene mutations were found in two of three pediatric pleuropulmonary blastoma (PPB) cases. These mutations correlated with a fatal outcome, suggesting p53 inactivation in PPB pathogenesis.
Area of Science:
- Pediatric Oncology
- Cancer Genetics
- Molecular Pathology
Background:
- Pleuropulmonary blastoma (PPB) is a rare pediatric thoracic tumor.
- Previous studies identified chromosomal abnormalities but lacked evidence of gene mutations.
- PPB shares pathological similarities with rhabdomyosarcoma, where p53 mutations are common.
Observation:
- This study investigated p53 mutations in three PPB patient samples.
- Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing were employed.
- Two out of three PPB tumors harbored distinct p53 mutations.
Findings:
- Specific p53 mutations identified include Val to Leu substitution at codon 173 and ArgArg to TrpCys substitution at codons 282-283.
- Analysis suggested p53 inactivation, as only the mutated allele was detected in the tumors.
- Patients with p53 mutations experienced fatal outcomes, while the patient without mutations remains disease-free.
Implications:
- p53 inactivation may be a nonrandom genetic event in PPB pathogenesis and outcome.
- These findings suggest p53 status could be a prognostic marker for PPB.
- Further research on a larger cohort is warranted to confirm the role of p53 in PPB.